Sfoglia per AUTORE
VITELLO S
Collezione AO Cuneo

  

Items : 3

2018
AO Cuneo

Borelli B; Moretto R; Lonardi S; Bonetti A; Antoniotti C; Pietrantonio F; Masi G; Burgio V; Marmorino F; Salvatore L; Rossini D; Zaniboni A; Zucchelli G; Martignetti A; Di Battista M; Pella N; Passardi A; Boccaccino A; Leone F; Colombo C; Granetto C; Vannini F; Marsico VA; Martinelli E; Antonuzzo L; Vitello S; Delliponti L; Boni L; Cremolini C; et alii...

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2016 May;27(5):843-9. doi: 10.1093/annonc/mdw052. Epub 2016 Feb 9.
2016
AO Cuneo
AOU Città della Salute di Torino

Bustreo S; Ronzoni M; Buonadonna A; Bergamo F; Tomasello G; Tonini G; Allegrini G; Vitello S; Rossini D; Moretto R; Chiara S; Mancini ML; Granetto C; Lonardi S; Masi G; Loupakis F; Cremolini C; Barbara C; Boni L; Falcone A;

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2015 Jun;26(6):1188-1194. doi: 10.1093/annonc/mdv112. Epub 2015 Feb 23.
2015
AO Cuneo
AOU Città della Salute di Torino

Di Donato S; Granetto C; Bonetti A; D'Amico M; Vitello S; Longarini R; Barone C; Tonini G; Spadi R; Zaniboni A; Tomasello G; Cortesi E; Salvatore L; Masi G; Lonardi S; Antoniotti C; Cremolini C; Loupakis F; Boni L; Falcone A;